P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL
Nooka, A., Cohen, A., Lee, H., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E., Chaudhry, M., Hultcrantz, M., Kortüm, K.M., Richardson, P., Popat, R., Sborov, D., Hakim, S., Lewis, E., Bhushan, B., Gorsh, B., Gupta, I., Opalinska, J., Lonial, S.
Published in HemaSphere (09.05.2023)
Published in HemaSphere (09.05.2023)
Get full text
Journal Article
P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐6 ARM‐A INTERIM ANALYSIS
Quach, H., Gironella, M., Lee, C., Popat, R., Cannell, P., Kasinathan, R. S., Chopra, B., Rogers, R., Ferron‐Brady, G., Shafi‐Harji, S., Patel, N., Opalinska, J., Gupta, I., Augustson, B.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14
Hultcrantz, M., Kleinman, D., Ghataorhe, P., Mckeown, A., He, W., Ling, T., Jewell, R. C., Byrne, J., Eliason, L., Scott, E., Opalinska, J.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism
Busse, D, Busch, F W, Bohnenstengel, F, Eichelbaum, M, Fischer, P, Opalinska, J, Schumacher, K, Schweizer, E, Kroemer, H K
Published in Journal of clinical oncology (01.05.1997)
Published in Journal of clinical oncology (01.05.1997)
Get more information
Journal Article
Asymmetric reduction of ketones and β-keto esters by (S)-1-phenylethanol dehydrogenase from denitrifying bacterium Aromatoleum aromaticum
Dudzik, A, Snoch, W, Borowiecki, P, Opalinska-Piskorz, J, Witko, M, Heider, J, Szaleniec, M
Published in Applied microbiology and biotechnology (01.06.2015)
Published in Applied microbiology and biotechnology (01.06.2015)
Get full text
Journal Article
Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules
Opalinska, J. B., Kalota, A., Gifford, Lida K., Lu, Ponzy, Jen, Kuang-Yu, Pradeepkumar, P. I., Barman, J., Kim, T. K., Swider, C. R., Chattopadhyaya, J., Gewirtz, A. M.
Published in Nucleic acids research (01.01.2004)
Published in Nucleic acids research (01.01.2004)
Get full text
Journal Article
Rheology of potato starch chemically modified with microwave-assisted reactions
Staroszczyk, H., Fiedorowicz, M., Opalińska-Piskorz, J., Tylingo, R.
Published in Food science & technology (01.09.2013)
Published in Food science & technology (01.09.2013)
Get full text
Journal Article
1105TiP - DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Trudel, S., Nooka, A., Fecteau, D., Talekar, M., Jewell, R.C., Williams, D., Evans, J., Opalinska, J.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Trudel, S., Nooka, A., Fecteau, D., Talekar, M., Jewell, R.C., Williams, D., Evans, J., Opalinska, J.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo
Montes de Oca, Rocio, Alavi, Alireza S, Vitali, Nick, Bhattacharya, Sabyasachi, Blackwell, Christina, Patel, Krupa, Seestaller-Wehr, Laura, Kaczynski, Heather, Shi, Hong, Dobrzynski, Eric, Obert, Leslie, Tsvetkov, Lyuben, Cooper, David C, Jackson, Heather, Bojczuk, Paul, Forveille, Sabrina, Kepp, Oliver, Sauvat, Allan, Kroemer, Guido, Creighton-Gutteridge, Mark, Yang, Jingsong, Hopson, Chris, Yanamandra, Niranjan, Shelton, Christopher, Mayes, Patrick, Opalinska, Joanna, Barnette, Mary, Srinivasan, Roopa, Smothers, James, Hoos, Axel
Published in Molecular cancer therapeutics (01.10.2021)
Published in Molecular cancer therapeutics (01.10.2021)
Get full text
Journal Article
1105TiPDREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Trudel, S, Nooka, A, Fecteau, D, Talekar, M, Jewell, R C, Williams, D, Evans, J, Opalinska, J
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE‐AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM‐14
Hultcrantz, M., Kleinman, D., Ghataorhe, P., Mckeown, A., He, W., Ling, T., Jewell, R. C., Byrne, J., Eliason, L., Scott, E., Opalinska, J.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)
A. Medaglia, A.K. Nooka, M.V.M. Manteca, N. Bahlis, K. Weisel, A. Oriol, A.A. Alonso, A. Suvannasankha, B. Holkova, K. Luptakova, D. Fecteau, B.E. Kremer, M. Nichols, D. Williams, D.A Smith, R.C. Jewell, R. Montes de Oca, J. Opalinska, S. Trudel
Published in Hematology reports (01.09.2020)
Get full text
Published in Hematology reports (01.09.2020)
Journal Article
Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up
A. Medaglia, A.D. Cohen, H.C. Lee, S. Trudel, A-O. Abdallah, N. Callander, E. Libby, L. Karlin, S. Lonial, L. Womersley, J. Baron, E. Lewis, K. Nungesser, I. Gupta, J. Opalinska
Published in Hematology reports (01.09.2020)
Get full text
Published in Hematology reports (01.09.2020)
Journal Article
Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics
S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia
Published in Hematology reports (01.09.2020)
Get full text
Published in Hematology reports (01.09.2020)
Journal Article
Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study
Burris, H. A., Siu, L. L., Infante, J. R., Wheler, J. J., Kurkjian, C., Opalinska, J., Smith, D. A., Antal, J. M., Gauvin, J. L., Gonzalez, T., Adams, L. M., Bedard, P., Gerecitano, J. F., Kurzrock, R., Moore, K. N., Morris, S. R., Aghajanian, C.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article